secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-103005
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena presents preclinical data for IK-930 with TEAD1 selectivity and wider therapeutic window vs panTEAD
--------------------------------------------------------------------------------

- IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.
- Average urinary protein-to-creatinine ratios and histopathology predicted a therapeutic index <1 for panTEAD vs broad window for IK-930.
- IK-930 plus osimertinib delayed emergence of drug-tolerant persister cells in preclinical EGFR-mutant NSCLC models.
- Phase 1 monotherapy dose escalation ongoing; initial monotherapy clinical data expected in 2H 2023.
- Cash >$155M as of filing; runway into 2025; partnered IK-175 with BMS potentially $50M opt-in fees by early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/0001193125-23-103005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523103005/d460401d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-103005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer